Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 5/20 | 0.43 |
| ▸ | CTSB | P07858 | 4/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7423984 | 0.88 | SCN9A (0.50) | SCN9ANPY1R | |
| SCHEMBL8521032 | 0.86 | CCKBR (0.45) | KLK7KLK5SCN9ANPY1R | |
| SCHEMBL5712987 | 0.86 | CCKBR (0.45) | KLK7KLK5SCN9ANPY1R | |
| SCHEMBL26745906 | 0.85 | KLK7 (0.46) | KLK7KLK5KMT2ACTSLCTSB | |
| SCHEMBL29048164 | 0.84 | SMN1; SMN2 (0.57) | KMT2AL3MBTL1SCN9ANPY1R | |
| SCHEMBL26317923 | 0.83 | KMT2A (0.45) | KLK7KLK5KMT2AL3MBTL1CTSL | |
| SCHEMBL7283564 | 0.83 | MME (0.54) | KLK7KLK5SCN9ANPY1R | |
| SCHEMBL644741 | 0.83 | SCN9A (0.47) | CTSLSCN9A | |
| SCHEMBL7283565 | 0.83 | MME (0.54) | KLK7KLK5SCN9ANPY1R | |
| SCHEMBL17948796 | 0.82 | CASP3 (0.50) | KMT2AL3MBTL1CTSLSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | KLK7 3185/4885KLK5 4298/4885KMT2A 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.